A benzoxazolylurea inhibits VraS and enhances antimicrobials against vancomycin intermediate-resistant Staphylococcus aureus
bioRxiv (Cold Spring Harbor Laboratory)(2023)
摘要
ABSTRACT Vancomycin intermediate-resistant Staphylococcus aureus (VISA) is a pathogen of concern. VraS, a histidine kinase, facilitates the VISA phenotype. Here, we reveal a benzoxazolylurea that directly inhibits VraS and enhances vancomycin to below the clinical breakpoint against an archetypal VISA strain. To the best of our knowledge, this is the first direct VraS inhibitor ever reported that shows significant enhancement of vancomycin against VISA.
更多查看译文
关键词
benzoxazolylurea,antimicrobials,vancomycin,staphylococcus aureus,intermediate-resistant
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要